Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00262483 | Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C | PHASE2 | COMPLETED | 12 | — | — | Dec 1, 2005 | Apr 1, 2006 | Dec 21, 2007 | 2 | United States, Puerto Rico |
| NCT00251199 | VX-950 and Peginterferon for Hepatitis C | PHASE1 | COMPLETED | 20 | — | — | Oct 1, 2005 | Mar 1, 2006 | Dec 21, 2007 | 2 | Germany, Netherlands |
| Name | Type | Description |
|---|---|---|
| VX-950 | DRUG | - |
| ribavirin | DRUG | - |
| peginterferon alfa-2a | DRUG | - |
| peginterferon | DRUG | - |
Inclusion Criteria: * Infected with hepatitis C virus Exclusion Criteria: * Contraindications to peginterferon or ribavirin therapy.
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | — | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | — | Undisclosed |